Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA

UEI: SLED_2B10D3DD815F5293

AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA is a federal contractor, registered under UEI SLED_2B10D3DD815F5293. It has been awarded $816,311,230 across 4 federal contracts. Primary work spans Research and Development in Biotechnology (except Nanobiotechnology) and In-Vitro Diagnostic Substance Manufacturing. Top awarding agencies include National Institutes Of Health Niaid and CDC Office Of Acquisition Services.

Contact Information

Registration and classification details

Registration

UEI Code

SLED_2B10D3DD815F5293

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
National Institutes Of Health Niaid$721.8M88.4%
CDC Office Of Acquisition Services$94.6M11.6%
Awards by NAICS
541714 - Research and Development in Biotechnology (except Nanobiotechnology)$721.8M88.4%
325413 - In-Vitro Diagnostic Substance Manufacturing$94.6M11.6%
Awards by Agency Over Time
Export
Awards by Place of Performance

Open opportunities in AMERICAN TYPE CULTURE COLLECTION Manassas VA 20110 USA's top NAICS codes and agencies

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem Cells
Solicitation # NIH-NOI-PCA-NIA-01590
The National Institute on Aging (NIA), under the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), has issued a Notice of Intent to Sole Source for the validation and optimization of ONE-STEP tagging in human induced pluripotent stem cells (iPSCs). This acquisition aims to support the iPSC Neurodegenerative Disease Initiative (iNDI) and the Center of Alzheimer’s Disease and Related Dementias (CARD) by generating functionally engineered iPSC lines for research into Alzheimer’s disease and related dementias. The project involves high-activity guide identification, Bxb1 mRNA and cargo plasmid delivery optimization, and the generation of ADRD variant, MAPT 4R, and wild-type process-control clones. All deliverables must be repository-ready, meeting strict quality control standards including long-read sequencing, karyotype analysis, and SNP arrays to ensure scientific continuity and data integrity. The government intends to award this contract to The Jackson Laboratory, citing them as the only responsible source capable of meeting the requirements under FAR 6.302-1 and FAR 13.501(a). This determination is based on the laboratory's unique continuity with the existing iNDI program, established workflows for specific background lines, and proven success in large-scale CRISPR/Cas9 engineering. The total estimated contract value is 3,353,115.00 dollars, covering a base year from September 1, 2026, to August 31, 2027, and an option year extending to August 31, 2028. While this is a sole-source intent, the government will consider capability statements from other sources submitted by August 21, 2026, to determine if adequate competition exists.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 2 days
View Details
NAICS: 541511
New
Federal
Modernized VAERS Reporting Application
Solicitation # 75D301-26-Q-00146
The Centers for Disease Control and Prevention (CDC) Office of Acquisition Services is soliciting a Firm Fixed Price contract under solicitation 75D301-26-Q-00146 to develop a modernized reporting application for the Vaccine Adverse Event Reporting System (VAERS). This small business set-aside project focuses on enhancing the reporting experience for consumers and healthcare providers through a redesigned landing page, branching logic workflows, intelligent form validation, and reactive design elements. The scope includes the design, testing, and deployment of a responsive web application within the CDC's MS Azure cloud environment, ensuring full compliance with HIPAA, the Privacy Act, FISMA, and Section 508 accessibility standards. The period of performance is scheduled from September 28, 2026, to June 27, 2027. The contract includes a primary task for the application development and two not-to-exceed travel CLINs totaling 63,000 dollars. Award selection is based on a best-value tradeoff, prioritizing technical approach and management capability over price and past performance. Key deliverables include UX artifacts, a fully functional application, and comprehensive security documentation such as System Security Plans and POA&Ms. The contractor must adhere to strict security protocols, including FIPS 140-2 validated encryption and specific personnel suitability investigations ranging from Tier 1 to Tier 5.
CDC Office Of Acquisition Services

POSTED

1 day ago

DEADLINE

in 16 days
View Details